Skip to content
The Nexus
DossierENTITY

Mo-Rez

Coverage of Mo-Rez in the Nexus archive.

Earliest in view: Apr 12 · 15:02 UTCMost recent: Apr 12 · 15:02 UTC
Co-mentioned in this coverage
GSKorganization1Luke Mielsperson1Ovarian cancertopic1Endometrial cancertopic1
Recent coverage
  • HEALTHApr 12 · 15:02 UTCTHE GUARDIAN WORLD
    GSK reports promising early results in ovarian and womb cancer drug trial

    GSK reported early trial results showing Mo-Rez reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The CEO, Luke Miels, is advancing drug development efforts for the potential blockbuster treatment.

Mo-Rez · Dossier · The Nexus